PCSK9 inhibitors in clinical practice: Novel directions and new experiences-Reference-Cited by-同舟云学术

PCSK9 inhibitors in clinical practice: Novel directions and new experiences

Published:2020-07 Issue:4 Volume:61 Page:241-245
ISSN:1109-9666
Container-title:Hellenic Journal of Cardiology
language:en
Short-container-title:Hellenic Journal of Cardiology

Author:

Rallidis Loukianos S.,Skoumas Ioannis,Liberopoulos Evangelos N.,Vlachopoulos Charalambos,Kiouri Estela,Koutagiar Iosif,Anastasiou Georgia,Kosmas Nikolaos^ORCID,Elisaf Moses S.,Tousoulis Dimitrios,Iliodromitis Efstathios

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins;Baigent;Lancet,2005

2. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial;Giugliano;JAMA Cardiol,2017

3. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry;Kotseva;Eur J Prev Cardiol,2019

4. EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology;De Backer;Atherosclerosis,2015

5. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins;Rallidis;Atherosclerosis,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database;International Journal of Cardiology Cardiovascular Risk and Prevention;2024-06

2. Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study;Biomedicines;2024-01-26

3. The Link between miRNAs and PCKS9 in Atherosclerosis;Current Medicinal Chemistry;2023-11-16

4. Current Insights on Dyslipidaemia Management for Prevention of Atherosclerotic Cardiovascular Disease: A Malaysian Perspective;Malaysian Journal of Medical Sciences;2023-02-28

5. Protein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies (PCSK9mab) in Clinical Practice at Secondary Care – Real World Multicentre Experience;Cureus;2022-12-28